Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Cagrilintide studies

164 journal papers mention Cagrilintide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Cagrilintide is safe, effective or approved for any use.

Compare Cagrilintide prices, from €59.95 →

Papers
164
113 articles, 51 reviews
Earliest paper
2021
Most papers in 2026 (72)
Open access
58%
free to read somewhere
Reviews
31%
of all papers listed

What kind of studies

Of 105 papers in PubMed that mention Cagrilintide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials15
  • Other clinical trials0
  • Meta-analyses and systematic reviews11
  • Other reviews50
  • Case reports0
  • Animal studies only6
  • Studies in humans64

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Cagrilintide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
44
Completed
24
Ongoing or planned
18
Phase 1
17
Phase 2
5
Phase 3
22
  1. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

    NCT07607587RecruitingPhase 1started 2026-05-29

  2. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    NCT06221969CompletedPhase 3started 2024-01-16

  3. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

    NCT06534411CompletedPhase 3started 2024-11-05

  4. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

    NCT07282613RecruitingPhase 3started 2026-08-04

  5. Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    NCT07220759Active, not recruitingPhase 3started 2025-11-05

The five most recently updated studies. See all 44 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

2021 to 2026, peak 72 papers in a year. The latest year may still be incomplete.

2021: 8 papers2022: 5 papers2023: 11 papers2024: 24 papers2025: 44 papers2026: 72 papers20212026

Where it is published

  1. Diabetes32 papers
  2. The Lancet8 papers
  3. Peptides5 papers
  4. Diabetes Obesity and Metabolism5 papers
  5. The Lancet Diabetes & Endocrinology5 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

    Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen et al. · The Lancet · 2023

    Randomized trial · Phase 2Open access · CC BY-NC-ND333 citationsRead the open copy →

  2. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

    David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco et al. · The Lancet · 2021

    Randomized trial · Phase 2Open access278 citationsRead the open copy →

  3. Development of Cagrilintide, a Long-Acting Amylin Analogue

    Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl et al. · Journal of Medicinal Chemistry · 2021

    Study in humansOpen access · CC BY-NC-ND129 citationsRead the open copy →

  4. Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

    Anna Thorsø Larsen, Khaled Elhady Mohamed, Nina Sonne et al. · Biomedicine & Pharmacotherapy · 2022

    Animal studyOpen access · CC BY-NC-ND38 citationsRead the open copy →

  5. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

    Alexandra Oliveira Carvas, Andrea Stephanie Leuthardt, Patricia Kulka et al. · EBioMedicine · 2025

    Animal studyOpen access · CC BY25 citationsRead the open copy →

  6. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

    Deep Dutta, Lakshmi Nagendra, BG Harish et al. · Indian Journal of Endocrinology and Metabolism · 2024

    ReviewOpen access · CC BY-NC-SA17 citationsRead the open copy →

  7. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors

    Jianjun Cao, Matthew J. Belousoff, Rachel M. Johnson et al. · Nature Communications · 2025

    Study in humansOpen access · CC BY-NC-ND16 citationsRead the open copy →

  8. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance

    Mette Q. Ludwig, Bernd Coester, Desiree Gordian et al. · Nature Metabolism · 2026

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  9. Characterization of 0839 – A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide

    Sanaz Gabery, Tine Glendorf, Borja Ballarín-González et al. · Life Sciences · 2025

    Study in humansOpen access · CC BY-NC-ND3 citationsRead the open copy →

  10. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

    Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu-Khazneh et al. · Endocrinology Diabetes & Metabolism · 2026

    Study in humansOpen access · CC BY2 citationsRead the open copy →

  11. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

    Hammad Rao, Sumet Kumar, Sheikh Muhammad Ebtehaj Ali et al. · Journal of Diabetes & Metabolic Disorders · 2026

    ReviewOpen access2 citationsRead the open copy →

  12. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors

    Yi-min Gu, Qingning Yuan, Xin Li et al. · Acta Pharmacologica Sinica · 2025

    Study in humansOpen access2 citationsRead the open copy →

  13. The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies

    Yuxin Wang, Zhien Feng, Lexiang Yu · The Innovation Medicine · 2025

    Open access · CC BY2 citationsRead the open copy →

  14. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

    Maria B. N. Gabe, Rainard Fuhr, Angela Sinn et al. · Diabetes Obesity and Metabolism · 2024

    Randomized trialOpen access · CC BY-NC2 citationsRead the open copy →

  15. Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes

    Nasser Mikhail · Clinical Research and Clinical Trials · 2023

    Open access · CC BY2 citationsRead the open copy →

  16. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide

    Mette J. F. Nielsen, Niels‐Peter Becker, Helene H. Hansen Duus et al. · Clinical Pharmacokinetics · 2026

    Randomized trial · Phase 1Open access · CC BY-NC1 citationsRead the open copy →

  17. Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

    Yange Meng, Ting Jin, Luping Ren et al. · Journal of Clinical Question · 2025

    Open access · CC BY1 citationsRead the open copy →

  18. Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity

    Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski et al. · Journal of Education Health and Sport · 2026

    Open access · CC BY-NC-SARead the open copy →

  19. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

    Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BYRead the open copy →

  20. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  21. 26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS

    Ravi Medarametla, Ashok Runkana, Naga Praneeth Vakkalagadda et al. · Journal of the American College of Cardiology · 2026

    Open accessRead the open copy →

  22. Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis

    Ting Jin, Yange Meng, Luping Ren et al. · Journal of Clinical Question · 2025

    Open access · CC BYRead the open copy →

LatestName in title or abstract

  1. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  2. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis

    Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram et al. · Diabetes Obesity and Metabolism · 2026

    ReviewOpen access · CC BYRead the open copy →

  3. Dose-specific efficacy and safety of cagrisema in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

    Bilal Wazir Khan, Muhammad Huzaifa Khattak, Muhammad Yahya et al. · BMC Endocrine Disorders · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  4. The Hyperamylinemia–Inflammation–Coronary Artery Disease Axis in Type 2 Diabetes Mellitus: Exploring Amylin as a Potential Cardiometabolic Therapeutic Target

    International Journal of Drug Delivery Technology · 2026

    Open accessRead the open copy →

  5. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis

    Zehra Khatoon Rasool, Rajvi Shah, Ansharah E Zinnia Batool et al. · Frontiers in Endocrinology · 2026

    Meta-analysisOpen access · CC BYRead the open copy →

  6. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

    Matthew Aaron Cavender, Ania M. Jastreboff, ALICE Y.Y. CHENG et al. · American Heart Journal · 2026

    Open access · CC BYRead the open copy →

  7. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats

    LISBETH MILLING PETERSEN, Filip Krag Knop, Carel Wynand le Roux et al. · Molecular Metabolism · 2026

    Open access · CC BY-NC-NDRead the open copy →

  8. Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

    Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  9. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

    Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic et al. · Diabetes Therapy · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  10. Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity

    Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski et al. · Journal of Education Health and Sport · 2026

    Open access · CC BY-NC-SARead the open copy →

  11. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

    Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BYRead the open copy →

  12. ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES

    Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  13. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

    Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  14. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials

    Chuhan Shao, Hanmo Lin, Jie Yu et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  15. Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding

    Marcos J. Sanchez-Navarro, Carlie Zhang, Heath D. Schmidt et al. · Physiology & Behavior · 2026

    Animal studyOpen access · CC BY-NC-NDRead the open copy →

  16. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

    Sophia L. Fischer, Tito Borner · Pharmacological Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  17. Amycretin in the Treatment of Obesity: Hormonal Mechanisms, Clinical Evidence, and Therapeutic Perspectives of the New Generation of Incretin Agonists

    Carolina Fátima Gioia Nava, Jaimiro Azevedo de Aquino Filho, Digilany Aparecida de Souza Lemes et al. · International Journal of Health Science · 2026

    Open accessRead the open copy →

  18. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials

    Deshi Chen, Bing Ma, Hao Sun et al. · BMJ Medicine · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  19. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

    Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen et al. · Diabetes Obesity and Metabolism · 2026

    Randomized trialOpen access · CC BYRead the open copy →

  20. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism

    Jo Edward Lewis, Mireia Montaner, Danaé Nuzzaci et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BY3 citationsRead the open copy →

  21. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

    Rohit Seth Loomba, Jacob George, Laurent Castéra et al. · The Lancet. Gastroenterology & hepatology · 2026

    Randomized trial · Phase 2Open access · CC BY6 citationsRead the open copy →

  22. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

    Abdulhameed Alhazmi, Carel Wynand le Roux · Diabetes Obesity and Metabolism · 2026

    ReviewOpen access · CC BY-NC-ND1 citationsRead the open copy →

  23. Efektivitas Obat Generasi Baru (Amylin-based, CagriSema) dalam Mengelola Obesitas sebagai Penyakit Kronis

    Yoga Prasetyo, Zahra Mutiara Salsabila · MUARA KESEHATAN Jurnal Ilmiah Ilmu Kesehatan · 2026

    Open access · CC BY-SARead the open copy →

  24. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  25. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

    Kailei Nong, Qingyang Shi, Xinran Xie et al. · BMJ · 2026

    Systematic reviewOpen access · CC BY-NC10 citationsRead the open copy →

  26. Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes

    Walter Gulisano, Gitte Ter-Borch, Paul Brown et al. · Journal of Diabetes Science and Technology · 2026

    Open accessRead the open copy →

  27. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance

    Mette Q. Ludwig, Bernd Coester, Desiree Gordian et al. · Nature Metabolism · 2026

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  28. AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY

    Nikolinka Koleva, Boris Dinkov, Galya Stavreva · Journal of IMAB - Annual Proceeding (Scientific Papers) · 2026

    Open access · CC BY-SARead the open copy →

Each list shows up to 40 papers.See all 164 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.